耐利福平/耐多药肺结核患者接受长期治疗后治疗效果不佳的影响因素。

IF 1.6 Q4 INFECTIOUS DISEASES International Journal of Mycobacteriology Pub Date : 2024-07-01 Epub Date: 2024-09-14 DOI:10.4103/ijmy.ijmy_132_24
Aylin Babalik, Ahmet Balikçi, Ayla Turkar, Nazli Huma Teke, Fatma Kübra Demir, Simge Yavuz, Emine Nur Koç, Senem Gündüz, Büşra Ergeç, Hasan Can Alagöz, Eren Sarioğlu, Zeki Kiliçaslan
{"title":"耐利福平/耐多药肺结核患者接受长期治疗后治疗效果不佳的影响因素。","authors":"Aylin Babalik, Ahmet Balikçi, Ayla Turkar, Nazli Huma Teke, Fatma Kübra Demir, Simge Yavuz, Emine Nur Koç, Senem Gündüz, Büşra Ergeç, Hasan Can Alagöz, Eren Sarioğlu, Zeki Kiliçaslan","doi":"10.4103/ijmy.ijmy_132_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug-resistant tuberculosis (DR-TB) poses a significant threat to global TB control and remains a major public health issue. This study aims to evaluate treatment outcomes and identify risk factors for unfavorable outcomes in patients with multi-DR-TB (MDR-TB) treated at a major reference hospital in Istanbul.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 413 patients with rifampicin-resistant and MDR-TB who received treatment between January 1, 2013, and December 31, 2023, at the University of Health Sciences Süreyyapaşa Chest Diseases Training and Research Hospital. Patients were treated following the World Health Organization and national guidelines, with regimens tailored to individual drug resistance profiles and side effect management. Demographic data, comorbidities, microbiological follow-up, drug resistance patterns, treatment regimens, and radiological findings were analyzed.</p><p><strong>Results: </strong>Treatment success was achieved in 350 patients (84.74%). Thirty-two patients (7.74%) were lost to follow-up, and 32 patients (7.74%) died. Logistic regression analysis identified several factors associated with unfavorable treatment outcomes: comorbidities (odds ratio [OR]: 7.555, P = 0.001), quinolone resistance (OR: 3.695, P = 0.030), and bronchiectasis (OR: 4.126, P = 0.013). Additional significant factors included male gender (P = 0.007), foreign-born status (P = 0.013), age over 35 years (P = 0.002), previous treatment history (P = 0.058), and drug side effects (P = 0.012).</p><p><strong>Conclusion: </strong>The long-term regimen for MDR-TB was found to be highly successful, with an 84.74% treatment success rate. Effective treatment regimens, close patient follow-up, early recognition of side effects, and comprehensive management are crucial for achieving successful outcomes. Identifying and addressing risk factors such as comorbidities, drug resistance, and specific patient demographics can further improve treatment success rates. This study underscores the importance of tailored treatment strategies and robust patient management in combating MDR-TB.</p>","PeriodicalId":14133,"journal":{"name":"International Journal of Mycobacteriology","volume":"13 3","pages":"265-274"},"PeriodicalIF":1.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen.\",\"authors\":\"Aylin Babalik, Ahmet Balikçi, Ayla Turkar, Nazli Huma Teke, Fatma Kübra Demir, Simge Yavuz, Emine Nur Koç, Senem Gündüz, Büşra Ergeç, Hasan Can Alagöz, Eren Sarioğlu, Zeki Kiliçaslan\",\"doi\":\"10.4103/ijmy.ijmy_132_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Drug-resistant tuberculosis (DR-TB) poses a significant threat to global TB control and remains a major public health issue. This study aims to evaluate treatment outcomes and identify risk factors for unfavorable outcomes in patients with multi-DR-TB (MDR-TB) treated at a major reference hospital in Istanbul.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 413 patients with rifampicin-resistant and MDR-TB who received treatment between January 1, 2013, and December 31, 2023, at the University of Health Sciences Süreyyapaşa Chest Diseases Training and Research Hospital. Patients were treated following the World Health Organization and national guidelines, with regimens tailored to individual drug resistance profiles and side effect management. Demographic data, comorbidities, microbiological follow-up, drug resistance patterns, treatment regimens, and radiological findings were analyzed.</p><p><strong>Results: </strong>Treatment success was achieved in 350 patients (84.74%). Thirty-two patients (7.74%) were lost to follow-up, and 32 patients (7.74%) died. Logistic regression analysis identified several factors associated with unfavorable treatment outcomes: comorbidities (odds ratio [OR]: 7.555, P = 0.001), quinolone resistance (OR: 3.695, P = 0.030), and bronchiectasis (OR: 4.126, P = 0.013). Additional significant factors included male gender (P = 0.007), foreign-born status (P = 0.013), age over 35 years (P = 0.002), previous treatment history (P = 0.058), and drug side effects (P = 0.012).</p><p><strong>Conclusion: </strong>The long-term regimen for MDR-TB was found to be highly successful, with an 84.74% treatment success rate. Effective treatment regimens, close patient follow-up, early recognition of side effects, and comprehensive management are crucial for achieving successful outcomes. Identifying and addressing risk factors such as comorbidities, drug resistance, and specific patient demographics can further improve treatment success rates. This study underscores the importance of tailored treatment strategies and robust patient management in combating MDR-TB.</p>\",\"PeriodicalId\":14133,\"journal\":{\"name\":\"International Journal of Mycobacteriology\",\"volume\":\"13 3\",\"pages\":\"265-274\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Mycobacteriology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijmy.ijmy_132_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Mycobacteriology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijmy.ijmy_132_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:耐药结核病(DR-TB)对全球结核病控制构成重大威胁,仍然是一个重大的公共卫生问题。本研究旨在评估在伊斯坦布尔一家大型参考医院接受治疗的多重耐药结核病(MDR-TB)患者的治疗效果,并确定导致不利治疗效果的风险因素:我们对2013年1月1日至2023年12月31日期间在健康科学大学Süreyyapaşa胸部疾病培训与研究医院接受治疗的413名利福平耐药和MDR-TB患者进行了回顾性分析。患者按照世界卫生组织和国家指南接受治疗,并根据个人耐药性情况和副作用控制情况制定了治疗方案。对人口统计学数据、合并症、微生物学随访、耐药模式、治疗方案和放射学检查结果进行了分析:350名患者(84.74%)治疗成功。32名患者(7.74%)失去随访,32名患者(7.74%)死亡。逻辑回归分析确定了与不利治疗结果相关的几个因素:合并症(几率比 [OR]:7.555,P = 0.001)、喹诺酮耐药(OR:3.695,P = 0.030)和支气管扩张(OR:4.126,P = 0.013)。其他重要因素包括男性性别(P = 0.007)、外国出生身份(P = 0.013)、35 岁以上(P = 0.002)、既往治疗史(P = 0.058)和药物副作用(P = 0.012):结论:MDR-TB 的长期治疗方案非常成功,治疗成功率高达 84.74%。有效的治疗方案、对患者的密切随访、副作用的早期识别以及全面的管理是取得成功结果的关键。识别并解决合并症、耐药性和特定患者人口统计等风险因素可进一步提高治疗成功率。这项研究强调了量身定制的治疗策略和强有力的患者管理在抗击耐药结核病中的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen.

Background: Drug-resistant tuberculosis (DR-TB) poses a significant threat to global TB control and remains a major public health issue. This study aims to evaluate treatment outcomes and identify risk factors for unfavorable outcomes in patients with multi-DR-TB (MDR-TB) treated at a major reference hospital in Istanbul.

Methods: We conducted a retrospective analysis of 413 patients with rifampicin-resistant and MDR-TB who received treatment between January 1, 2013, and December 31, 2023, at the University of Health Sciences Süreyyapaşa Chest Diseases Training and Research Hospital. Patients were treated following the World Health Organization and national guidelines, with regimens tailored to individual drug resistance profiles and side effect management. Demographic data, comorbidities, microbiological follow-up, drug resistance patterns, treatment regimens, and radiological findings were analyzed.

Results: Treatment success was achieved in 350 patients (84.74%). Thirty-two patients (7.74%) were lost to follow-up, and 32 patients (7.74%) died. Logistic regression analysis identified several factors associated with unfavorable treatment outcomes: comorbidities (odds ratio [OR]: 7.555, P = 0.001), quinolone resistance (OR: 3.695, P = 0.030), and bronchiectasis (OR: 4.126, P = 0.013). Additional significant factors included male gender (P = 0.007), foreign-born status (P = 0.013), age over 35 years (P = 0.002), previous treatment history (P = 0.058), and drug side effects (P = 0.012).

Conclusion: The long-term regimen for MDR-TB was found to be highly successful, with an 84.74% treatment success rate. Effective treatment regimens, close patient follow-up, early recognition of side effects, and comprehensive management are crucial for achieving successful outcomes. Identifying and addressing risk factors such as comorbidities, drug resistance, and specific patient demographics can further improve treatment success rates. This study underscores the importance of tailored treatment strategies and robust patient management in combating MDR-TB.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.20
自引率
25.00%
发文量
62
审稿时长
7 weeks
期刊最新文献
Methods for the Inactivation of Mycobacterium tuberculosis: a Systematic Review of the Literature. Molecular Identification of Mycobacterium leprae in the Leprosy Patients. Optimal Positive End-expiratory Pressure Levels in Tuberculosis-associated Acute Respiratory Distress Syndrome. Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis. Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1